Yuvanci

Yuvanci combines Tadalafil and Macitentan for oral use, designed to support pulmonary arterial hypertension management. This combination therapy targets vascular resistance and blood flow in EU markets. Ideal for patients seeking integrated PAH treatment options.

Yuvanci is used to manage pulmonary arterial hypertension by improving exercise capacity and reducing symptoms. Tadalafil supports blood vessel relaxation, while Macitentan helps lower blood pressure in the lungs. It is prescribed for adults with WHO Group 1 PAH to enhance daily function and delay disease progression.

Users may experience improved breathing and reduced fatigue during physical activity. Some report enhanced stamina and fewer episodes of shortness of breath. Effects vary by individual and may take time to become noticeable. Regular monitoring is recommended to assess progress.

Store Yuvanci at room temperature away from moisture and heat. Keep out of reach of children and pets. Do not use if the packaging is damaged or the expiry date has passed. Consult a healthcare provider before starting or stopping this medication to ensure safety.

Avoid alcohol while taking Yuvanci, as it may increase side effects like dizziness. Certain medications, such as strong CYP3A inhibitors or nitrates, can interact with this combination. Always inform your doctor about all drugs, supplements, or herbal products you are using.